Steatotic Liver Disease: MASLD: Diagnosis Through Pharmacotherapy

0:00Welcome to Board Pearls. This is episode one of two of the Steatotic Liver Disease chapter, in the Liver Disease module. This episode is MASLD from the cardiometabolic-criteria diagnosis through pharmacotherapy: the positive diagnosis, lean disease and cryptogenic cirrhosis as the same entity, noninvasive fibrosis assessment, lifestyle and bariatric surgery, and the new drugs.

0:26The first thing to understand is that the current name reflects a change in how the diagnosis works. The old label was exclusionary, defined by what the patient wasn't doing, not drinking and no other liver disease, with a word that carried stigma without diagnostic content. The current framework replaces it with a positive diagnosis built on cardiometabolic criteria, so metabolic dysfunction-associated steatotic liver disease requires hepatic steatosis on imaging or biopsy plus at least one of five cardiometabolic features, naming the disease for its driver rather than for what the patient is not doing. The five criteria are worth holding as one picture: obesity by body mass index over twenty-five, or over twenty-three in Asian populations, or by waist circumference; a glycemic criterion, fasting glucose over a hundred, an HbA1c at or above five point seven, or diabetes; blood pressure at or above one thirty over eighty-five or treatment; triglycerides at or above one hundred fifty or treatment; and a low HDL, under forty in men or fifty in women, or treatment. One criterion is enough, a deliberate change from the older metabolic syndrome definition requiring three, because any one cardiometabolic feature plus steatosis carries the same driver biology even before the full cluster accumulates.

1:41Within the umbrella, the steatohepatitis form adds hepatocyte ballooning and lobular inflammation to bland steatosis, and it's the form that drives fibrosis, with most patients having bland steatosis and a quarter to a third having steatohepatitis at any given time. The prognostic anchor is not the inflammatory grade and not the transaminase level, it's the fibrosis stage, because liver-related mortality climbs steeply from the earliest stages to cirrhosis, so reading prognosis through fibrosis stage rather than the transaminases is what separates correct management from the older instinct to chase the ALT. The alcohol relationship is now a continuum rather than a binary exclusion: pure metabolic disease sits below a threshold of alcohol per week, pure alcohol disease sits above a higher threshold, and in between is the intermediate category for the metabolically loaded patient who also drinks moderately, with the conversion the boards expect being that one standard US drink is fourteen grams, so four drinks a night five nights a week sits in that intermediate zone for a man and in the alcohol-disease range for a woman. The intermediate category reads on histology like the metabolic disease with a heavier inflammatory layer and a worse prognosis than either alone, which is why it exists, and the management leans hard on alcohol reduction even below the alcohol-disease threshold because the combined biology accelerates injury.

3:06The mechanism beneath all of this is insulin resistance plus genetic susceptibility plus lipotoxicity. Peripheral insulin resistance fails to suppress fat breakdown, so free fatty acid flux to the liver rises, hyperinsulinemia drives hepatic fat synthesis, and dietary fructose adds another lipogenic signal, so supply exceeds the liver's export capacity and bland steatosis results. Progression to steatohepatitis happens when the lipid load shifts from inert triglyceride to lipotoxic intermediates that disrupt mitochondria, generate reactive oxygen species, deplete glutathione, and drive cell stress, so the hepatocyte apoptoses, the macrophages produce inflammatory cytokines, and the stellate cell deposits collagen, in a multi-hit network rather than the old two-hit model. The unifying point is a mismatch between fatty acid supply and the hepatocyte's capacity to dispose of the load. The genetic architecture is dominated by three variants the boards test: a variant in PNPLA3 that impairs lipid-droplet triglyceride hydrolysis and accelerates the whole progression to cirrhosis and cancer, common in Hispanic populations at around half, which also amplifies alcohol-associated disease and is the genetic bridge between the two; a variant in TM6SF2 that traps triglyceride in the liver by impairing lipoprotein secretion, so the carrier has high liver fat but paradoxically low serum LDL and reduced cardiovascular risk; and a protective loss-of-function variant that's become a drug target. The genetics explain why one patient with severe metabolic dysfunction stays at bland steatosis while another develops cirrhosis from a comparable exposure.

4:38Lean disease is the patient with steatosis and cardiometabolic dysfunction whose body mass index is under twenty-five, a notable share of cases and overrepresented in Asian populations, where the biology is the same insulin resistance and visceral adiposity but the body mass index doesn't capture it because the fat sits intra-abdominally and intra-hepatically, so the clue is the cardiometabolic profile in a lean frame, and it's not benign, with cardiovascular and liver mortality at least as high as in obese disease, partly because the normal weight falsely reassures, with the weight-loss target shifted down to three to five percent because the room for loss is smaller. Cryptogenic cirrhosis is the other piece of the same picture: cirrhosis with no identifiable etiology after a complete workup is, in the majority, burned-out steatohepatitis, because progression to cirrhosis extinguishes the histologic markers, the steatosis disappears as the parenchyma remodels and inflammation quiets, leaving a bland-appearing cirrhotic liver in a patient whose metabolic profile points back to the steatotic origin, so cryptogenic cirrhosis in a patient with cardiometabolic features is steatohepatitis cirrhosis until proven otherwise, corroborated by recurrent steatosis after transplant, and the same logic applies to cryptogenic liver cancer sitting on a metabolic substrate that lost its lipid signature.

5:41Once the diagnosis is in place, the question is no longer whether there's steatosis, it's whether there's advanced fibrosis. Biopsy was historically the answer but carries a small complication rate, samples a tiny fraction of the organ, and suffers inter-rater variability, so the modern approach uses noninvasive testing in a tiered sequence, reserving biopsy for residual uncertainty. FIB-4 is the entry-level test, using age, transaminases, and platelets, essentially free off a routine panel, with cutoffs of under one point three to rule out advanced fibrosis with high negative predictive value and over two point six seven to identify high-risk patients, the interval between triggering a second-tier test, with the age-over-sixty-five trap where the lower cutoff shifts to two point zero because the formula weights age heavily, and it's good as a screen but not good enough to be the final answer in the indeterminate zone. The enhanced liver fibrosis serum panel is a useful adjunct when FIB-4 is indeterminate or elastography is unavailable, with defined thresholds for advanced fibrosis and for high risk of liver-related events. Transient elastography is the second-tier test in most pathways, where a value under eight kilopascals rules out advanced fibrosis, over twelve to fourteen is consistent with cirrhosis, and eight to twelve is the indeterminate zone, with a controlled attenuation parameter on the same probe quantifying steatosis, but it has confounders the boards exploit, a failure rate worst at high body mass index, and false elevations from severe steatosis, hepatic congestion, biliary obstruction, acute hepatitis, and recent food intake, so a high reading in a recently fed patient with congestion or obstruction is an artifact, not advanced fibrosis. The one threshold that crosses into portal hypertension is a stiffness over twenty kilopascals with a platelet count under a hundred fifty thousand, which indicates clinically significant portal hypertension and triggers variceal screening. MR elastography is the most accurate noninvasive test, with a very low failure rate, generating a whole-liver stiffness map less subject to sampling error, and it's the answer when transient elastography is unreliable in severe obesity, ascites, or narrow intercostal spaces, with iron overload the dominant confounder, and an MRI fat-fraction sequence quantifying steatosis with high precision.

8:00The algorithm runs in a clear sequence: FIB-4 first as a screen, with concordant low results from FIB-4 and elastography effectively ruling out advanced fibrosis so the patient stays in lifestyle management with reassessment every year or two, concordant high results making biopsy unnecessary in many cases so the patient is staged as advanced, and discordant results, an indeterminate scan, or a clinical question that staging would change pushing toward MR elastography or biopsy, which is reserved for when staging will change management or the diagnosis remains in question.

8:25Once fibrosis is staged, management runs from lifestyle at the base to pharmacotherapy at the top, with bariatric surgery in between. Lifestyle modification is the only intervention with histologic-improvement evidence across the full spectrum, and the dose-response of weight loss to liver outcomes is one of the few precise relationships in hepatology: five percent total body weight loss reduces steatosis, seven to ten percent resolves steatohepatitis in most patients and reduces ballooning and inflammation, and ten percent or more produces fibrosis regression in many, while loss under five percent rarely changes histology. So the target is a graded one, with seven to ten percent the practical goal for most patients with steatohepatitis and five percent the floor for any meaningful response, shifted down to three to five percent in lean disease. The Mediterranean pattern has the strongest evidence, olive oil as the dominant fat with fish, vegetables, legumes, whole grains, and nuts and limited red and processed meat, partly by reducing the saturated fat and refined carbohydrate that drive fat synthesis and partly by adding anti-inflammatory omega-threes and polyphenols, with specific eliminations mattering, especially commercial fructose in sweetened beverages and ultra-processed foods, which is the dietary lever with the highest yield. Other diets work too if they produce a caloric deficit, but the Mediterranean pattern is preferred for its cardiovascular co-benefits, which matter because cardiovascular disease, not liver disease, is the leading cause of death here. Exercise improves the disease independent of weight loss by driving skeletal-muscle glucose uptake and reducing hepatic lipid, with a target of a hundred fifty to three hundred minutes of moderate activity a week plus resistance training to preserve lean mass, and coffee, three or more cups daily, is associated with reduced fibrosis progression and is a low-cost recommendation, while alcohol is restricted and eliminated entirely with significant fibrosis.

10:17Bariatric surgery is the most effective weight-loss intervention for severe obesity and produces the most dramatic outcomes, with the standard criteria being a body mass index over forty, or over thirty-five with obesity-related comorbidities, after supervised weight-loss attempts, and in the data steatosis improves in most patients, steatohepatitis resolves in over half, and fibrosis improves in about a third at a year, with sleeve gastrectomy and gastric bypass both effective, the bypass producing more weight loss and diabetes remission and the sleeve a lower complication profile so it's now more common, including in compensated cirrhosis. Bariatric surgery in cirrhosis is the high-risk question the boards love, and the instinct to refuse the cirrhotic patient is wrong for the right patient: compensated steatohepatitis cirrhosis with preserved synthetic function, a low MELD, no decompensation history, and no clinically significant portal hypertension can undergo surgery at experienced centers, with the portal-hypertension threshold that excludes it being a hepatic venous pressure gradient over ten in most centers, over fifteen an absolute contraindication, and ten to fifteen or non-bleeding varices a case-by-case zone. So the favored vignette is the obese steatohepatitis-cirrhosis patient with a single-digit MELD, normal platelets, no ascites, and no variceal bleeding, and the answer is yes, at an experienced center, after confirming preserved function and no significant portal hypertension, with sleeve gastrectomy generally preferred.

11:35Pharmacotherapy is where the field changed most recently, because until the last couple of years every drug used was off-label, and that's been reset by two approvals: resmetirom became the first drug approved for steatohepatitis, and semaglutide became the first GLP-1 agonist approved for it, both for non-cirrhotic disease with moderate fibrosis, with pioglitazone for the diabetic patient and vitamin E for the non-diabetic on top of lifestyle. Resmetirom is an oral, liver-directed, thyroid-hormone-receptor-beta-selective agonist, and the mechanism is that the beta receptor is the dominant one in the liver driving mitochondrial fatty acid oxidation and bile acid metabolism while the alpha receptor drives the cardiac and bone effects, so beta-selectivity produces hepatic metabolic activation without thyroid toxicity. In its trial it resolved steatohepatitis in roughly a quarter to a third of treated patients versus far fewer on placebo, with fibrosis improvement in about a quarter, and it's approved for non-cirrhotic disease with moderate fibrosis, given for a year with reassessment. Its interactions matter: it inhibits the liver uptake transporters, so it limits some statin doses, atorvastatin to a maximum of twenty milligrams and others similarly, warrants caution with clopidogrel, and is contraindicated with gemfibrozil, and it's not approved for compensated cirrhosis because those patients were excluded. Semaglutide is the GLP-1 option, working through central appetite suppression, delayed gastric emptying, and improved insulin sensitivity, dosed at the higher weekly dose, and in its trial it resolved steatohepatitis in a majority versus a third on placebo with fibrosis improvement in more than a third, approved for non-cirrhotic disease with moderate fibrosis as an adjunct to diet and activity. Its clinical use case is the patient with obesity and diabetes, where it treats all three problems at once and the diabetes and weight indications already justify it, with tirzepatide the dual agonist producing even larger weight loss and showing steatohepatitis resolution but not yet approved for it, and the class side effects dominated by early nausea and gastroparesis-like symptoms. So the choice between resmetirom and semaglutide turns on the dominant comorbidity: semaglutide for the patient with obesity and diabetes, and resmetirom for the patient who's plateaued on lifestyle and needs a liver-directed drug or can't take a GLP-1.

14:03Pioglitazone targets PPAR-gamma to improve insulin sensitivity with downstream reduction in steatosis and improvement in histology, recommended for biopsy-proven steatohepatitis in patients with type two diabetes, with side effects that matter, weight gain, heart failure exacerbation so it's avoided in advanced heart failure, increased fracture risk in postmenopausal women, and a debated bladder cancer association, counterbalanced by reduced cardiovascular events in diabetes, which matters because that's what kills these patients. Vitamin E at eight hundred international units daily improves histology in many non-diabetic patients with biopsy-proven steatohepatitis as an antioxidant quenching the reactive oxygen species, with cautions being a prostate cancer signal, a hemorrhagic stroke association at high doses, and a controversial mortality signal, so it's not recommended in diabetics, in cirrhosis, or without biopsy-proven disease. The drugs to know that didn't work include the farnesoid X receptor agonist obeticholic acid, which showed fibrosis improvement but was declined for approval because of pruritus and an adverse lipid profile, pentoxifylline, and a long list of fibrates, ursodeoxycholic acid, and omega-threes that showed no histologic benefit, and statins, which aren't a steatohepatitis treatment but are safe in the disease and shouldn't be withheld when indicated for cardiovascular risk, since the old concern about statin hepatotoxicity in steatotic livers has been dismissed, so they're safe to start and continue with stable elevated transaminases and reduce cardiovascular mortality in this population.

15:27So the way of thinking is that this is a positive diagnosis built on cardiometabolic criteria, with fibrosis stage, not the transaminase or steatosis severity, as the prognostic anchor, and a tiered noninvasive sequence of FIB-4 into transient elastography into MR elastography or biopsy quantifying fibrosis without the needle. Management runs from lifestyle graded by weight-loss target, through bariatric surgery for the right patient including compensated cirrhosis without significant portal hypertension, to pharmacotherapy, whose map now has resmetirom and semaglutide as on-label options for non-cirrhotic moderate-fibrosis disease, with pioglitazone for the diabetic and vitamin E for the non-diabetic biopsy-proven patient. And cryptogenic cirrhosis with cardiometabolic features is burned-out steatohepatitis, while lean disease in a patient with the metabolic profile and a normal weight is the same disease in a thinner frame.

16:24The next episode moves along the alcohol continuum to alcohol-associated liver disease across the spectrum, working through steroid therapy for severe alcoholic hepatitis with the day-seven nonresponder rule, and the early transplant pathway for selected patients that replaced the old six-month sobriety requirement.

16:40For the full chapter, the practice vignettes, and the topic-tagged question bank, head to board pearls dot com. You'll find the rest of the series on Apple Podcasts, Spotify, or wherever you listen to podcasts. That brings us to the end of episode one of two of chapter twenty-one, and I'll see you in the next one.